Latest news with #ConsolidatedFinancialStatements
Cision Canada
a day ago
- Business
- Cision Canada
Cargojet Announces Inaugural Issuer Credit Rating of BBB (low) With a Stable Trend by Morningstar DBRS
MISSISSAUGA, ON, June 19, 2025 /CNW/ - Cargojet Inc. (" Cargojet" or the " Corporation") (TSX: CJT) today announced that Morningstar DBRS has assigned the Corporation an investment-grade issuer credit rating of BBB (low), with a stable trend. In assigning the rating, Morningstar DBRS cited Cargojet's contracted recurring revenue profile, efficient operations, leading market position in the Canadian domestic overnight air cargo market, and commitment to maintaining leverage within its publicly stated target range. "The assignment of an investment-grade credit validates the strength of our diversified portfolio of Domestic, Charters and ACMI offerings and disciplined approach to cost management," said Jamie Porteous, Co-Chief Executive Officer. "This achievement reinforces our strategic objectives of strengthening our financial position while continuing to build a platform focused on long-term sustainable growth. It also provides us the flexibility to pursue opportunities to improve our cost of capital and strengthen our balance sheet depending on market conditions" said Pauline Dhillon, Co-Chief Executive Officer. The Corporation also announced that it has posted an updated investor presentation to the Investor section of its website at: About Cargojet Cargojet is Canada's leading provider of time sensitive premium air cargo services to all major cities across North America, providing dedicated, ACMI and international charter services and carries over 25,000,000 pounds of cargo weekly. Cargojet operates its network with its own fleet of 41 cargo aircraft. Notice on Forward-Looking Statements: Certain statements contained herein constitute "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements look into the future and provide an opinion as to the effect of certain events and trends on the business. Forward-looking statements may include words such as "plans", "intends", "anticipates", "should", "estimates", "expects", "believes", "indicates", "targeting", "suggests" and similar expressions, and includes statements relating to potential opportunities to improve the Corporation's cost of capital and strengthen its balance sheet. These forward-looking statements are based on current expectations and entail various risks and uncertainties. Reference should be made to the Corporation's most recent Annual Information Form filed with the Canadian securities regulators, and its most recent Consolidated Financial Statements and Notes thereto and related Management's Discussion and Analysis, for a summary of major risks. Actual results may materially differ from expectations, if known and unknown risks or uncertainties affect our business, or if our estimates or assumptions prove inaccurate. Without limiting the foregoing, there can be no assurance that the Corporation will maintain an investment grade credit rating or improve its cost of capital on favourable terms. The forward-looking statements contained in this news release represent Cargojet's expectations as of the date of this news release (or as of the date they are otherwise stated to be made) and are subject to change after such date. However, Cargojet disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information, future events or otherwise, except as required under applicable securities laws. In the event Cargojet does update any forward-looking statement, no inference should be made that Cargojet will make additional updates with respect to that statement, related matters, or any other forward-looking statement.
Yahoo
4 days ago
- Business
- Yahoo
Subsea 7 - contract award offshore Norway
Luxembourg – 17 June 2025 - Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) today announced the award of a substantial1 contract offshore Norway. Subsea7's scope includes engineering, procurement, construction and installation (EPCI) of pipeline bundles, spools, protection covers and tie-ins using key vessels from Subsea7's fleet. Project management and engineering will commence immediately at Subsea7's offices in Stavanger, Norway and Aberdeen, Scotland. Fabrication of pipeline bundles will take place at Wester, Scotland. Offshore operations are expected to take place in 2025-2027. Erik Femsteinevik, Vice President for Subsea7 Norway said: "We are excited to have been awarded this project. Our collaboration with our clients leverages our collective experience from past and current projects. By engaging early in the field development process, we can optimise design solutions and contribute to a positive final investment decision. Subsea7 looks forward to a safe, efficient, and reliable field development." No further details are disclosed at this time. Subsea7 defines a substantial contract as being between $150 million and $300 million. *******************************************************************************Subsea7 is a global leader in the delivery of offshore projects and services for the evolving energy industry, creating sustainable value by being the industry's partner and employer of choice in delivering the efficient offshore solutions the world needs. Subsea7 is listed on the Oslo Børs (SUBC), ISIN LU0075646355, LEI 222100AIF0CBCY80AH62. ******************************************************************************* Contact for investment community enquiries:Katherine TonksInvestor Relations DirectorTel +44 20 8210 5568ir@ Contact for media enquiries:Jan Roger MoksnesCommunications ManagerTel +47 Forward-Looking Statements: This document may contain 'forward-looking statements' (within the meaning of the safe harbour provisions of the U.S. Private Securities Litigation Reform Act of 1995). These statements relate to our current expectations, beliefs, intentions, assumptions or strategies regarding the future and are subject to known and unknown risks that could cause actual results, performance or events to differ materially from those expressed or implied in these statements. Forward-looking statements may be identified by the use of words such as 'anticipate', 'believe', 'estimate', 'expect', 'future', 'goal', 'intend', 'likely' 'may', 'plan', 'project', 'seek', 'should', 'strategy' 'will', and similar expressions. The principal risks which could affect future operations of the Group are described in the 'Risk Management' section of the Group's Annual Report and Consolidated Financial Statements. Factors that may cause actual and future results and trends to differ materially from our forward-looking statements include (but are not limited to): (i) our ability to deliver fixed price projects in accordance with client expectations and within the parameters of our bids, and to avoid cost overruns; (ii) our ability to collect receivables, negotiate variation orders and collect the related revenue; (iii) our ability to recover costs on significant projects; (iv) capital expenditure by oil and gas companies, which is affected by fluctuations in the price of, and demand for, crude oil and natural gas; (v) unanticipated delays or cancellation of projects included in our backlog; (vi) competition and price fluctuations in the markets and businesses in which we operate; (vii) the loss of, or deterioration in our relationship with, any significant clients; (viii) the outcome of legal proceedings or governmental inquiries; (ix) uncertainties inherent in operating internationally, including economic, political and social instability, boycotts or embargoes, labour unrest, changes in foreign governmental regulations, corruption and currency fluctuations; (x) the effects of a pandemic or epidemic or a natural disaster; (xi) liability to third parties for the failure of our joint venture partners to fulfil their obligations; (xii) changes in, or our failure to comply with, applicable laws and regulations (including regulatory measures addressing climate change); (xiii) operating hazards, including spills, environmental damage, personal or property damage and business interruptions caused by adverse weather; (xiv) equipment or mechanical failures, which could increase costs, impair revenue and result in penalties for failure to meet project completion requirements; (xv) the timely delivery of vessels on order and the timely completion of ship conversion programmes; (xvi) our ability to keep pace with technological changes and the impact of potential information technology, cyber security or data security breaches; (xvii) global availability at scale and commercially viability of suitable alternative vessel fuels; and (xviii) the effectiveness of our disclosure controls and procedures and internal control over financial reporting. Many of these factors are beyond our ability to control or predict. Given these uncertainties, you should not place undue reliance on the forward-looking statements. Each forward-looking statement speaks only as of the date of this document. We undertake no obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange release was published by Katherine Tonks, Investor Relations, Subsea7, on 17 June 2025 at 16:40 CET. Attachment SUBC Norway June 2025
Yahoo
12-06-2025
- Business
- Yahoo
RadView Software Ltd. Announces Agenda for Annual General Meeting
RA'ANANA, Israel, June 12, 2025 (GLOBE NEWSWIRE) -- RadView Software Ltd. (OTCMKTS:RDVWF) today announced that its Annual General Meeting of Shareholders will be held on July 23, 2025 at 15:00 PM (Israel time) at the offices of the Company, 4 Dolev Street, Raanana, 4366204, Israel The record date for the meeting is June 18, 2025. The agenda of the meeting is as follows: To re-elect Mr. Shai Beilis, Mr. Avi Fried, Mr. Ori Gal and Mr. Assaf Katan to the Company's Board of Directors, to serve until the next annual general meeting of shareholders and until their successors have been duly elected and qualified; To re-elect Mr. Hillik Nissani and Ms. Tamar Naor to the Company's Board of Directors as external directors, to hold office for 3 years, commencing on the date of their re-election; To set the compensation of the External Directors (comprised of Director Fees and a grant of additional options); To set the compensation of each of Mr. Ori Gal and Mr. Assaf Katan, directors of the Company; To approve and ratify the compensation of Mr. Firas Matar, the CEO of the Company. To approve the renewal of the Company's directors' and officers' liability insurance policy with a coverage of $3,000,000 and the Company's indemnification and exemption of directors and officers; To reapprove the Company's Compensation Policy; To approve an amendment to the Convertible Loan Agreements with the Company's controlling shareholder, Formula Ventures (Holdings) Ltd, and other certain lenders; To approve the Convertible Loan Agreements (2022) with the Company's controlling shareholder, Formula Ventures (Holdings) Ltd, and other certain lenders, as amended; To reapprove the Management Services Agreements with each of the Company's controlling shareholders, Formula Ventures Ltd. and Mr. Avi Fried; To appoint BDO, as the Company's Independent Auditors, for each of the fiscal years ending December 31, 2022, December 31, 2023 and December 31, 2024 and for such additional period until the next annual general meeting of shareholders; and To review the Auditor's Report and the Company's Consolidated Financial Statements for the fiscal years ended December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023. Proposals No. 1, 3, 4 and 11 are ordinary resolutions, which require the affirmative vote of a majority of the shares. Proposals 2, 5, 6 , 7, 8, 9 and 10 are special resolutions, which have other majority requirements, as more fully described in the proxy statement. The presentation to the shareholders of the Company's Consolidated Financial Statements for the fiscal years ended December 31, 2020, December 31, 2021, December 31, 2022 and December 31, 2023 described in Proposal 12 does not involve a vote of the Company's shareholders. The Board recommends the approval of each of these proposals. The presence, in person or by proxy, of at least two shareholders holding at least 33⅓% of the voting rights, will constitute a quorum at the meeting. If within one-half of an hour from the time appointed for the meeting a quorum is not present, the Meeting will be adjourned to the same day in the next week, at the same time and place. Additional Information and Where to Find It In connection with the meeting, RadView will send to its shareholders as of the record date a proxy statement describing the various matters to be voted upon at the meeting, along with a proxy card enabling them to indicate their vote on each matter. Copies of the resolutions to be adopted at the meeting, and the Company's Consolidated Financial Statements will be available to any shareholder entitled to vote at the meeting, at the Company's offices during regular business hours or upon written request, submitted to the Company. You can contact the Company by phone at +1(908)5267756, or by email, at Finance@ About RadView RadView helps companies perfect their web and mobile applications with the most reliable and flexible performance engineering platform available, for more than 25 years. We address the performance requirements of such applications throughout their product life-cycle, from initial design through development, deployment, and ongoing changes and upgrades. Visit or call in to access your portfolio
Yahoo
02-06-2025
- Business
- Yahoo
AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the 'Company' or 'Avricore') reports on its result for the first quarter of 2025 and its progress towards expansion objectives for the balance of the year. For the three months ended March 31, 2025 the Company realized revenues of $434,061 with a gross profit of $346,297. The Company recorded a comprehensive loss of $77,300 with a net increase in cash of $137,068. Plan the Work – Work the Plan The Company is currently executing its plan to significantly expand HealthTab, its wholly owned turnkey point-of-care testing (POCT) platform that empowers pharmacies to become proactive community diagnostic centers, in the United Kingdom — a decision aligned with the region's robust healthcare market and significant investment in pharmacy-led services. To realize its goals, the Company has ensured its cash position is strong and has the assets needed to capitalize on scale up demand. Therefore, while its previously announced scale down of revenues within Canada has taken effect, the Company continues to be very well positioned to realize its objectives. 'Every day, we're proving just how valuable HealthTab™ can be in the hands of pharmacists,' said Hector Bremner, CEO of Avricore Health. 'The NHS is paving the way for expanded pharmacy services, and our work in the London feasibility study gives us real confidence that HealthTab™ will be part of that future.' Tackling the Need Healthcare systems globally are under increasing pressure due to budget constraints, clinician shortages, and rising demand for services. In Canada, over 6 million people lack access to a family doctor, and among those who do, only 29% receive timely care. Compounding the challenge, nearly a third of family doctors are expected to retire or leave the profession within the next three years. In the UK, with just 25% of physicians serving as GPs, individual practitioners are managing caseloads averaging 2,300 patients each. As these strains intensify, pharmacy is emerging as a key player in delivering primary care services. HealthTab™ is at the forefront of this shift—offering pharmacists tools to conduct essential screenings, identify urgent care needs, and forge deeper patient relationships. The platform reduces the burden on traditional healthcare settings and helps drive efficiencies in care delivery. The market demand for point-of-care solutions continues to grow, accelerated by the need for cost-effective, scalable, and decentralized care. HealthTab™ is uniquely positioned to meet this demand, providing innovative solutions where and when patients need them most. Financial Snapshot The following financial data for the three years is derived from the Annual Audited Consolidated Financial Statements and should be read in conjunction with the Consolidated Financial Statements. 2024 2023 2022 Total revenue $ 4,785,711 $ 3,485,147 $ 1,768,374 Loss from operations $ (668,977) $ (701,215) $ (818,228) Loss per share – basic and diluted $ (0.01) $ (0.01) $ (0.01) Total assets $ 2,298,544 $ 2,538,205 $ 2,568,983 Total current liabilities (1) $ 330,817 $ 529,218 $ 604,893 Total non-current financial liabilities Nil Nil Nil (1) 2022 Current liabilities include deferred revenue of $252,000 for which the Company completed delivery in Q1 2023. Quarterly Financial Information The following table highlights selected unaudited consolidated financial data for each of the eight most recent quarters. These results are not necessarily indicative of results for any future period and you should not rely on these results to predict future performance. Quarter Ended March2025 Dec2024 Sep2024 June2024 March2024 Dec2023 Sep2023 June2023 Revenue 434,061 1,421,076 1,195,122 1,045,206 1,124,307 1,354,403 953,454 548,049 Gross profit 346,297 589,930 434,791 370,775 484,791 501,466 261,778 229,471 Share-based compensation 61,861 174,013 338,089 1,598 27,464 142,765 304,328 168,518 Comprehensive income (loss) (77,300) (712,521) (179,065) 54,022 168,537 59,584 (285,062) (284,225) Net profit (loss)/share (0.00) (0.01) (0.00) 0.00 0.00 (0.00) (0.00) (0.00) Total Assets 2,139,345 2,298,544 3,024,103 2,618,384 2,798,058 2,538,205 2,453,136 2,143,810 HealthTab™ Fast Facts Point of Care Testing Market to reach $93.21 Billion USD in 2030 (Source) Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source) Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source) Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (Source) There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK. About HealthTab™ HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API. About Avricore Health Inc. Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab™, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. Contact: Avricore Health Bremner, CEO 604-773-8943info@ Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
02-06-2025
- Business
- Yahoo
AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the 'Company' or 'Avricore') reports on its result for the first quarter of 2025 and its progress towards expansion objectives for the balance of the year. For the three months ended March 31, 2025 the Company realized revenues of $434,061 with a gross profit of $346,297. The Company recorded a comprehensive loss of $77,300 with a net increase in cash of $137,068. Plan the Work – Work the Plan The Company is currently executing its plan to significantly expand HealthTab, its wholly owned turnkey point-of-care testing (POCT) platform that empowers pharmacies to become proactive community diagnostic centers, in the United Kingdom — a decision aligned with the region's robust healthcare market and significant investment in pharmacy-led services. To realize its goals, the Company has ensured its cash position is strong and has the assets needed to capitalize on scale up demand. Therefore, while its previously announced scale down of revenues within Canada has taken effect, the Company continues to be very well positioned to realize its objectives. 'Every day, we're proving just how valuable HealthTab™ can be in the hands of pharmacists,' said Hector Bremner, CEO of Avricore Health. 'The NHS is paving the way for expanded pharmacy services, and our work in the London feasibility study gives us real confidence that HealthTab™ will be part of that future.' Tackling the Need Healthcare systems globally are under increasing pressure due to budget constraints, clinician shortages, and rising demand for services. In Canada, over 6 million people lack access to a family doctor, and among those who do, only 29% receive timely care. Compounding the challenge, nearly a third of family doctors are expected to retire or leave the profession within the next three years. In the UK, with just 25% of physicians serving as GPs, individual practitioners are managing caseloads averaging 2,300 patients each. As these strains intensify, pharmacy is emerging as a key player in delivering primary care services. HealthTab™ is at the forefront of this shift—offering pharmacists tools to conduct essential screenings, identify urgent care needs, and forge deeper patient relationships. The platform reduces the burden on traditional healthcare settings and helps drive efficiencies in care delivery. The market demand for point-of-care solutions continues to grow, accelerated by the need for cost-effective, scalable, and decentralized care. HealthTab™ is uniquely positioned to meet this demand, providing innovative solutions where and when patients need them most. Financial Snapshot The following financial data for the three years is derived from the Annual Audited Consolidated Financial Statements and should be read in conjunction with the Consolidated Financial Statements. 2024 2023 2022 Total revenue $ 4,785,711 $ 3,485,147 $ 1,768,374 Loss from operations $ (668,977) $ (701,215) $ (818,228) Loss per share – basic and diluted $ (0.01) $ (0.01) $ (0.01) Total assets $ 2,298,544 $ 2,538,205 $ 2,568,983 Total current liabilities (1) $ 330,817 $ 529,218 $ 604,893 Total non-current financial liabilities Nil Nil Nil (1) 2022 Current liabilities include deferred revenue of $252,000 for which the Company completed delivery in Q1 2023. Quarterly Financial Information The following table highlights selected unaudited consolidated financial data for each of the eight most recent quarters. These results are not necessarily indicative of results for any future period and you should not rely on these results to predict future performance. Quarter Ended March2025 Dec2024 Sep2024 June2024 March2024 Dec2023 Sep2023 June2023 Revenue 434,061 1,421,076 1,195,122 1,045,206 1,124,307 1,354,403 953,454 548,049 Gross profit 346,297 589,930 434,791 370,775 484,791 501,466 261,778 229,471 Share-based compensation 61,861 174,013 338,089 1,598 27,464 142,765 304,328 168,518 Comprehensive income (loss) (77,300) (712,521) (179,065) 54,022 168,537 59,584 (285,062) (284,225) Net profit (loss)/share (0.00) (0.01) (0.00) 0.00 0.00 (0.00) (0.00) (0.00) Total Assets 2,139,345 2,298,544 3,024,103 2,618,384 2,798,058 2,538,205 2,453,136 2,143,810 HealthTab™ Fast Facts Point of Care Testing Market to reach $93.21 Billion USD in 2030 (Source) Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source) Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source) Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (Source) There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK. About HealthTab™ HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API. About Avricore Health Inc. Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. Through its flagship offering HealthTab™, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies. Contact: Avricore Health Bremner, CEO 604-773-8943info@ Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
